Nivolumab Injection

Phase 2Completed

0 watching 0 views this week⚡ Active

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Recurrent and/or Metastatic Platinum-refractory SCCHN

Conditions

Recurrent and/or Metastatic Platinum-refractory SCCHN

Trial Timeline

Jul 7, 2017 → May 31, 2022

NCT ID

NCT03226756

About Nivolumab Injection

Nivolumab Injection is a phase 2 stage product being developed by Bristol Myers Squibb for Recurrent and/or Metastatic Platinum-refractory SCCHN. The current trial status is completed. This product is registered under clinical trial identifier NCT03226756. Target conditions include Recurrent and/or Metastatic Platinum-refractory SCCHN.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (2)

NCT ID	Phase	Status	Start	Completion	Indication
NCT03715946	Phase 2	Completed	Nov 16, 2018	Mar 31, 2024	Carcinoma, Squamous Cell of Head and Neck
NCT03226756	Phase 2	Completed	Jul 7, 2017	May 31, 2022	Recurrent and/or Metastatic Platinum-refractory SCCHN

Competing Products

20 competing products in Recurrent and/or Metastatic Platinum-refractory SCCHN

See all competitors

Product	Company	Stage	Hype Score
KPL-914	Kiniksa Pharmaceuticals	Phase 2	47
KPL-387	Kiniksa Pharmaceuticals	Phase 2	47
Rilonacept + Placebo	Kiniksa Pharmaceuticals	Phase 3	72
Enzastaurin (LY317615) + Carboplatin	Eli Lilly	Phase 1	33
Zopapogene imadenovec (Zopa)	Precigen	Approved	80
PRGN-2012 - Phase I; Dose Level 1 + PRGN-2012 - Phase I; Dose Level 2 + PRGN-2012 - Phase II; Dose Level 2	Precigen	Phase 1/2	36
[203Pb]VMT01 + [212Pb]VMT01 + Nivolumab	Perspective Therapeutics	Phase 1/2	33
Ramucirumab + Pembrolizumab	Eli Lilly	Phase 2	52
Gemcitabine and UFTE chemotherapy	Yuhan	Phase 2	52
Raludotatug Deruxtecan + Carboplatin + Paclitaxel + Bevacizumab + Rescue Medication + Pembrolizumab	Daiichi Sankyo	Phase 1/2	41
Ifinatamab deruxtecan	Daiichi Sankyo	Phase 2	52
Trastuzumab Deruxtecan	Daiichi Sankyo	Phase 1	33
PLX3397	Daiichi Sankyo	Phase 2	52
erlotinib + etoposide	Astellas Pharma	Phase 2	52
Drug Combination Therapy	Sun Pharmaceutical	Phase 2	52
Niraparib + Anlotinib	Sun Pharmaceutical	Phase 2	52
Eribulin Mesylate	Eisai	Pre-clinical	23
Lenvatinib + Everolimus	Eisai	Phase 1/2	41
E7090	Eisai	Phase 2	52
Lenvatinib	Eisai	Phase 2	52

Other Products from Bristol Myers Squibb

DeucravacitinibApproved

Aripiprazole + Olanzapine + HaloperidolApproved

Irbesartan + CiprofibrateApproved

Entecavir + Lamivudine Placebo + Lamivudine + Entecavir PlaceboApproved

deucravacitinibApproved